{"success":true,"data":{"pressRelease":{"id":"151642","rtpr_id":"nPn9DcXg2a-20260924","ticker":"UNCY","exchange":"NASDAQ","all_tickers":["UNCY"],"title":"UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit","author":"PR Newswire","published_at":"2026-09-24T07:54:00.244Z","article_body":"UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit\nPR Newswire\n\nNEW YORK, Sept. 24, 2026\n\nNEW YORK, Sept. 24, 2026 /PRNewswire/ --\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\nsecurities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29,\n2025 and June 29, 2026, both dates inclusive (the \"Class Period\"), of the\nimportant November 2, 2026 lead plaintiff deadline.\n\nSo what: If you purchased Unicycive securities during the Class Period you may\nbe entitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWhat to do next: To join the Unicycive class action, go to\nhttps://rosenlegal.com/cases/unicycive-therapeutics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=1223194745&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than November 2,\n2026. A lead plaintiff is a representative party acting on behalf of other\nclass members in directing the litigation.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer\nrecognition. Many of these firms do not actually handle securities class\nactions, but are merely middlemen that refer clients or partner with law firms\nthat actually litigate the cases. Be wise in selecting counsel. The Rosen Law\nFirm represents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved the largest ever securities class action settlement against a\nChinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class\nAction Services for number of securities class action settlements in 2017. The\nfirm has been ranked in the top 4 each year since 2013 and has recovered\nbillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nDetails of the case: According to the lawsuit, throughout the Class Period,\ndefendants made materially false and misleading statements and/or failed to\ndisclose that: (1) Unicycive had not inspected its third-party manufacturing\nvendor's facility or otherwise audited the facility's compliance with current\ngood manufacturing practices; (2) as a result, Unicycive lacked a reasonable\nbasis to believe that the vendor had resolved the U.S. Food and Drug\nAdministration's (\"FDA\") cited deficiencies; (3) there was an undisclosed risk\nthat the FDA would require additional information about the vendor's\nfacility's manufacturing practices; (4) as a result of the foregoing, the\nregulatory approval of oxylanthanum carbonate (\"OLC\") was reasonably likely to\nbe delayed; and (5) as a result of the foregoing, defendants' positive\nstatements about Unicycive's business, operations, and prospects were\nmaterially misleading and/or lacked a reasonable basis. When the true details\nentered the market, the lawsuit claims that investors suffered damages.\n\nTo join the Unicycive class action, go to\nhttps://rosenlegal.com/cases/unicycive-therapeutics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=1223194745&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=3538169172&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=3900729088&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\n or on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=415067693&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n     Laurence Rosen, Esq.\n     Phillip Kim, Esq.\n     The Rosen Law Firm, P.A.\n     275 Madison Avenue, 40th Floor\n     New York, NY 10016\n     Tel: (212) 686-1060\n     Toll Free: (866) 767-3653\n     Fax: (212) 202-3827\n     case@rosenlegal.com (mailto:case@rosenlegal.com)\n     www.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=2237923532&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302888518.html\n(https://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302888518.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1118010/Rosen-Law-Firm-Logo.jpg?id=OA2968594\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn9DcXg2a-20260924","title":"UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit","author":"PR Newswire","ticker":"UNCY","created":"2026-09-24T07:54:00.244Z","tickers":["UNCY"],"exchange":"NASDAQ","article_body":"UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit\nPR Newswire\n\nNEW YORK, Sept. 24, 2026\n\nNEW YORK, Sept. 24, 2026 /PRNewswire/ --\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of\nsecurities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29,\n2025 and June 29, 2026, both dates inclusive (the \"Class Period\"), of the\nimportant November 2, 2026 lead plaintiff deadline.\n\nSo what: If you purchased Unicycive securities during the Class Period you may\nbe entitled to compensation without payment of any out of pocket fees or costs\nthrough a contingency fee arrangement.\n\nWhat to do next: To join the Unicycive class action, go to\nhttps://rosenlegal.com/cases/unicycive-therapeutics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=1223194745&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action. A class action lawsuit has already been filed. If you wish to\nserve as lead plaintiff, you must move the Court no later than November 2,\n2026. A lead plaintiff is a representative party acting on behalf of other\nclass members in directing the litigation.\n\nWhy Rosen Law: We encourage investors to select qualified counsel with a track\nrecord of success in leadership roles. Often, firms issuing notices do not\nhave comparable experience, resources, or any meaningful peer\nrecognition. Many of these firms do not actually handle securities class\nactions, but are merely middlemen that refer clients or partner with law firms\nthat actually litigate the cases. Be wise in selecting counsel. The Rosen Law\nFirm represents investors throughout the globe, concentrating its practice in\nsecurities class actions and shareholder derivative litigation. Rosen Law Firm\nhas achieved the largest ever securities class action settlement against a\nChinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class\nAction Services for number of securities class action settlements in 2017. The\nfirm has been ranked in the top 4 each year since 2013 and has recovered\nbillions of dollars for investors. In 2019 alone the firm secured over $438\nmillion for investors. In 2020, founding partner Laurence Rosen was named by\nlaw360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been\nrecognized by Lawdragon and Super Lawyers.\n\nDetails of the case: According to the lawsuit, throughout the Class Period,\ndefendants made materially false and misleading statements and/or failed to\ndisclose that: (1) Unicycive had not inspected its third-party manufacturing\nvendor's facility or otherwise audited the facility's compliance with current\ngood manufacturing practices; (2) as a result, Unicycive lacked a reasonable\nbasis to believe that the vendor had resolved the U.S. Food and Drug\nAdministration's (\"FDA\") cited deficiencies; (3) there was an undisclosed risk\nthat the FDA would require additional information about the vendor's\nfacility's manufacturing practices; (4) as a result of the foregoing, the\nregulatory approval of oxylanthanum carbonate (\"OLC\") was reasonably likely to\nbe delayed; and (5) as a result of the foregoing, defendants' positive\nstatements about Unicycive's business, operations, and prospects were\nmaterially misleading and/or lacked a reasonable basis. When the true details\nentered the market, the lawsuit claims that investors suffered damages.\n\nTo join the Unicycive class action, go to\nhttps://rosenlegal.com/cases/unicycive-therapeutics-inc/join\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=1223194745&u=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin&a=https%3A%2F%2Frosenlegal.com%2Fcases%2Funicycive-therapeutics-inc%2Fjoin)\n or call Phillip Kim, Esq. toll-free at 866-767-3653 or email\ncase@rosenlegal.com (mailto:case@rosenlegal.com)  for information on the\nclass action.\n\nNo Class Has Been Certified. Until a class is certified, you are not\nrepresented by counsel unless you retain one. You may select counsel of your\nchoice. You may also remain an absent class member and do nothing at this\npoint. An investor's ability to share in any potential future recovery is not\ndependent upon serving as lead plaintiff.\n\nFollow us for updates on LinkedIn:\nhttps://www.linkedin.com/company/the-rosen-law-firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=3538169172&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&a=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm)\n, on Twitter: https://twitter.com/rosen_firm\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=3900729088&u=https%3A%2F%2Ftwitter.com%2Frosen_firm&a=https%3A%2F%2Ftwitter.com%2Frosen_firm)\n or on Facebook: https://www.facebook.com/rosenlawfirm/\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=415067693&u=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&a=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome.\n\nContact Information:\n\n     Laurence Rosen, Esq.\n     Phillip Kim, Esq.\n     The Rosen Law Firm, P.A.\n     275 Madison Avenue, 40th Floor\n     New York, NY 10016\n     Tel: (212) 686-1060\n     Toll Free: (866) 767-3653\n     Fax: (212) 202-3827\n     case@rosenlegal.com (mailto:case@rosenlegal.com)\n     www.rosenlegal.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4782030-1&h=2237923532&u=http%3A%2F%2Fwww.rosenlegal.com%2F&a=www.rosenlegal.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302888518.html\n(https://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302888518.html)\n\nSOURCE THE ROSEN LAW FIRM, P. A.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1118010/Rosen-Law-Firm-Logo.jpg?id=OA2968594\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-24T07:54:00.295785598Z","server_sent_at_ms":1790236440295},"received_at":"2026-09-24T07:54:00.343Z","source_url":"https://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302888518.html"},"analysis":{"id":"140444","press_release_id":"151642","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["class action alleges undisclosed FDA manufacturing-vendor compliance risk that could delay OLC approval"],"eventType":"legal_litigation","narrative":"Rosen Law Firm issued a lead-plaintiff solicitation for a securities fraud class action against Unicycive Therapeutics covering purchasers between December 29, 2025 and June 29, 2026.\n\nThe suit alleges Unicycive failed to disclose it had not audited its third-party manufacturing vendor's FDA compliance, creating undisclosed risk that approval of oxylanthanum carbonate (OLC) would be delayed.\n\nThe release is law-firm marketing, not an issuer disclosure; the lead plaintiff deadline is November 2, 2026 and no class has been certified.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; monitor only for certified class or settlement."},"keyFigures":{"customDimensions":{"class_period_end":"June 29, 2026","class_period_start":"December 29, 2025","lead_plaintiff_deadline":"November 2, 2026"}},"quotedText":"No Class Has Been Certified.","namedEntities":{"people":[{"name":"Laurence Rosen","role":"founding partner, Rosen Law Firm"},{"name":"Phillip Kim","role":"attorney, Rosen Law Firm"}],"products":["oxylanthanum carbonate (OLC)"],"companies":[{"name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","relationship":"litigation target / issuer"},{"name":"Rosen Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Rosen Law Firm reminding investors of a lead plaintiff deadline. No class certified, no settlement, and no new issuer disclosure, though the allegations reference FDA/OLC approval delay risk already disclosed."},"tickerRelevance":{"others":[],"primary":"UNCY"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Rosen Law Firm issued a lead-plaintiff solicitation for a securities fraud class action against Unicycive Therapeutics covering purchasers between December 29, 2025 and June 29, 2026.\n\nThe suit alleges Unicycive failed to disclose it had not audited its third-party manufacturing vendor's FDA compliance, creating undisclosed risk that approval of oxylanthanum carbonate (OLC) would be delayed.\n\nThe release is law-firm marketing, not an issuer disclosure; the lead plaintiff deadline is November 2, 2026 and no class has been certified.","key_figures":{"customDimensions":{"class_period_end":"June 29, 2026","class_period_start":"December 29, 2025","lead_plaintiff_deadline":"November 2, 2026"}},"named_entities":{"people":[{"name":"Laurence Rosen","role":"founding partner, Rosen Law Firm"},{"name":"Phillip Kim","role":"attorney, Rosen Law Firm"}],"products":["oxylanthanum carbonate (OLC)"],"companies":[{"name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","relationship":"litigation target / issuer"},{"name":"Rosen Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-24T07:54:06.319Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":5962,"modelName":"glm-5.3-flashx"}}